RBC Capital on Gilead Sciences (GILD): 'We view this as a key positive for the HIV franchise'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $79.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
